Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 3/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.56 |
| ▸ | VDR | P11473 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8619016 | 0.96 | EPHA2 (0.59) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL20730017 | 0.96 | ABCC4 (0.59) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL18755838 | 0.95 | EPHA2 (0.58) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL13785415 | 0.94 | EPHA2 (0.58) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL10819278 | 0.94 | EPHA2 (0.58) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL13785424 | 0.94 | EPHA2 (0.62) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL13785429 | 0.94 | EPHA2 (0.58) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL10226250 | 0.91 | ABCC4 (0.56) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL16887835 | 0.91 | EPHA2 (0.61) | EPHA2ABCC4GPBAR1ABCC1VDR | |
| SCHEMBL18755598 | 0.91 | EPHA2 (0.58) | EPHA2ABCC4GPBAR1ABCC1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158601-B2 | Lipid formulation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100324120-A1 | LIPID FORMULATION | BANK OF AMERICA, N.A. | 2010-12-23 | — | — | US | disclosed |
| US-20090247608-A1 | Targeting Lipids | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247608-A1 | Targeting Lipids | LY96, ABHD10, APOB | EPHA2 957/4885ABCC4 1244/4885GPBAR1 2461/4885 |
| US-20100324120-A1 | LIPID FORMULATION | CETP, LIPA, SGMS1 | EPHA2 2018/4885ABCC4 775/4885GPBAR1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.